Grifols (NASDAQ:GRFS) Upgraded to “Strong-Buy” at Berenberg Bank

Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS) to a strong-buy rating in a report released on Tuesday morning, Zacks.com reports.

Grifols Stock Up 7.0 %

Shares of NASDAQ GRFS opened at $8.77 on Tuesday. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 8.68 and a beta of 0.50. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06. The firm’s fifty day moving average is $8.82 and its 200 day moving average is $7.77. Grifols has a 52 week low of $5.30 and a 52 week high of $12.15.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. On average, equities research analysts expect that Grifols will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently bought and sold shares of GRFS. B. Riley Wealth Advisors Inc. bought a new position in shares of Grifols during the second quarter valued at approximately $359,000. Sei Investments Co. lifted its position in shares of Grifols by 5.3% in the 1st quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock worth $14,091,000 after purchasing an additional 107,000 shares during the period. Team Hewins LLC lifted its position in shares of Grifols by 11.8% in the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 4,324 shares during the period. Hantz Financial Services Inc. bought a new stake in shares of Grifols during the 2nd quarter valued at about $1,235,000. Finally, Natixis Advisors LLC increased its position in shares of Grifols by 116.0% during the second quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock valued at $971,000 after buying an additional 82,723 shares during the period.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.